Logo (Actavis) 811 (Indomethacin Extended-Release 75 mg)
Pill with imprint Logo (Actavis) 811 is Beige, Capsule-shape and has been identified as Indomethacin Extended-Release 75 mg. It is supplied by Actavis Inc.
Indomethacin is used in the treatment of ankylosing spondylitis; back pain; bartter syndrome; bursitis; cluster headaches and belongs to the drug class Nonsteroidal anti-inflammatory drugs. prior to 30 weeks gestation: Risk cannot be ruled out during pregnancy. starting at 30 weeks gestation: There is positive evidence of human fetal risk during pregnancy. Indomethacin 75 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for Logo (Actavis) 811
Indomethacin Extended-Release
- Imprint
- Logo (Actavis) 811
- Strength
- 75 mg
- Color
- Beige
- Shape
- Capsule-shape
- Availability
- Prescription only
- Drug Class
- Nonsteroidal anti-inflammatory drugs
- Pregnancy Category
- C - Risk cannot be ruled out - prior to 30 weeks gestation, D - Positive evidence of risk - starting at 30 weeks gestation
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Actavis Inc.
- National Drug Code (NDC)
- 45963-0811
- Inactive Ingredients
-
methacrylic acid - methyl methacrylate copolymer (1:1),
povidone,
silicon dioxide,
sodium lauryl sulfate,
sucrose,
magnesium silicate,
gelatin,
ferrosoferric oxide,
potassium hydroxide,
propylene glycol,
shellac,
corn starch
Note: Inactive ingredients may vary.
Related images for "Logo (Actavis) 811"
More about indomethacin
- Side effects
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Reviews (196)
- Patient tips
- Drug images
- Compare alternatives
- Pricing & coupons
- En español
- Drug class: Nonsteroidal anti-inflammatory drugs
Patient resources
- Drug Information
- Indomethacin (Advanced Reading)
- Indomethacin Intravenous (Advanced Reading)
- Indomethacin Rectal (Advanced Reading)
- Indomethacin Capsules
Other brands
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.